Skip to content

Study · Randomized controlled trial · 2023

1 result

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.

Scherbak NN, Kruse R, Nyström T, Jendle J

Diabetes & metabolism journal22 Jun 2023Cited by 5 (Europe PMC)

PMID37349083 (opens in a new tab)PMCIDPMC10555542 (opens in a new tab)DOI10.4093/dmj.2022.0342 (opens in a new tab)PepBankPUB-37349083
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialOther

    In people with type 2 diabetes and subclinical heart failure, liraglutide treatment (with metformin) did not significantly influence levels of circulating microRNAs.

    In plain wordsIn people with type 2 diabetes and subclinical heart failure, liraglutide did not significantly change blood microRNA levels.

    Peptide
    Liraglutide
    Outcome
    No significant changeCirculating microRNA levels
    Study

    n: not reported in source

    Outcome group
    Gene expression · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide treatment did not significantly influence levels of circulating miRNAs.
    1 context sentence
    Summary · context
    The present study is a post hoc trial from a previously randomized control trial comparing liraglutide versus glimepiride both in combination with metformin in subjects with T2DM, and subclinical heart failure. miRNAs were determined in the subjects' serum samples with next generation sequencing.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01425580

Liraglutide and Heart Failure in Type 2 Diabetes

Thomas Nystromn = 62Jan 2012 to Aug 2016

Congestive Heart Failure · Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 1 Sept 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.